{"id":965172,"date":"2026-05-20T08:10:42","date_gmt":"2026-05-20T12:10:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/"},"modified":"2026-05-20T08:10:42","modified_gmt":"2026-05-20T12:10:42","slug":"protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/","title":{"rendered":"Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA"},"content":{"rendered":"
\n

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc.\u00a0<\/strong>(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced\u00a0that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Tuesday, May 26, 2026, at 9:30 am ET.<\/p>\n

A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company\u2019s website:\u00a0https:\/\/ir.protaratx.com<\/a>. The webcast will be archived for a limited time following the presentation.<\/p>\n

\n About\u00a0Protara Therapeutics, Inc.<\/strong>\n <\/p>\n

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara\u2019s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or na\u00efve to treatment with Bacillus Calmette-Gu\u00e9rin, as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit\u00a0www.protaratx.com<\/a>.<\/p>\n

Company Contact:<\/p>\n

Justine O’Malley
Protara Therapeutics
Justine.OMalley@protaratx.com<\/a>
646-817-2836<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc.\u00a0(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced\u00a0that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Tuesday, May 26, 2026, at 9:30 am ET. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company\u2019s website:\u00a0https:\/\/ir.protaratx.com. The webcast will be archived for a limited time following the presentation. About\u00a0Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara\u2019s portfolio includes its lead … <\/p>\n

Continue reading “Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-965172","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nProtara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc.\u00a0(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced\u00a0that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Tuesday, May 26, 2026, at 9:30 am ET. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company\u2019s website:\u00a0https:\/\/ir.protaratx.com. The webcast will be archived for a limited time following the presentation. About\u00a0Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara\u2019s portfolio includes its lead … Continue reading "Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T12:10:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMzE4OCM3NjExMjcxIzIxODk3Njg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA\",\"datePublished\":\"2026-05-20T12:10:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\\\/\"},\"wordCount\":253,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMzE4OCM3NjExMjcxIzIxODk3Njg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\\\/\",\"name\":\"Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMzE4OCM3NjExMjcxIzIxODk3Njg=\",\"datePublished\":\"2026-05-20T12:10:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMzE4OCM3NjExMjcxIzIxODk3Njg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMzE4OCM3NjExMjcxIzIxODk3Njg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/","og_locale":"en_US","og_type":"article","og_title":"Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Market Newsdesk","og_description":"NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc.\u00a0(Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced\u00a0that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Tuesday, May 26, 2026, at 9:30 am ET. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company\u2019s website:\u00a0https:\/\/ir.protaratx.com. The webcast will be archived for a limited time following the presentation. About\u00a0Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara\u2019s portfolio includes its lead … Continue reading \"Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-20T12:10:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMzE4OCM3NjExMjcxIzIxODk3Njg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA","datePublished":"2026-05-20T12:10:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/"},"wordCount":253,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMzE4OCM3NjExMjcxIzIxODk3Njg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/","name":"Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMzE4OCM3NjExMjcxIzIxODk3Njg=","datePublished":"2026-05-20T12:10:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMzE4OCM3NjExMjcxIzIxODk3Njg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMzE4OCM3NjExMjcxIzIxODk3Njg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-eha\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=965172"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/965172\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=965172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=965172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=965172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}